- Home
- TRST vs RIGL Comparison
TRST vs RIGL Comparison
Compare TRST & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRST | RIGL |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.5M | 628.4M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TRST | RIGL |
|---|---|---|
| Price | $43.50 | $28.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 107.9K | ★ 331.3K |
| Earning Date | 04-22-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 2.41 | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $66.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.33 | ★ $1.52 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $27.18 | $15.50 |
| 52 Week High | $48.45 | $52.24 |
Technical Indicators
Market Signals| Indicator | TRST | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 27.27 |
| Support Level | $42.03 | $27.23 |
| Resistance Level | $46.89 | $31.26 |
| Average True Range (ATR) | 1.21 | 1.74 |
| MACD | -0.23 | -0.48 |
| Stochastic Oscillator | 30.32 | 10.29 |
Price Performance
Historical ComparisonAbout TRST TrustCo Bank Corp NY
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.